pp-048 Oral solution
Dossier type
US CTD
Dossier status
Under development
Country of origin
United States
GMP approvals
FDA
Comments
For narcolepsy, targeting excessive daytime sleepiness and cataplexy.
Phase 1 clinical development, Small-molecule formulation
Designed as an optimized, next-generation oxybate formulation with significantly reduced sodium content and a once-nightly dosing profile, aiming to improve safety and convenience compared with high-sodium, twice-nightly oxybate therapies.
Route / form: Oral solution, once nightly.
Differentiation: Ultra-low sodium content and once-nightly dosing aim to improve cardiovascular safety, adherence, and sleep continuity vs. currently approved oxybate products.
Manufacturer #18873
A privately-held, mid-size biopharma firm focused on developing and marketing therapies for ADHD, pain, addiction and CNS disorders. It combines proprietary drug-delivery technology with global development and licensing efforts to deliver patient-friendly medications worldwide.
Manufacturer usually replies in 45 days